[The pathophysiology, clinical signs and therapy of urate nephropathy].
Tumor lysis syndrome is an oncologic emergency that is characterized by severe electrolyte abnormalities. The syndrome occurs in patients with lymphoproliferative malignancies, most often after chemotherapy, but also spontaneously. The pathophysiology involves tumor cell lysis resulting in the release of potassium, phosphate and uric acid. The deposition of uric acid and calcium phosphate crystals in the renal tubules may lead to acute renal failure. The treatment consists in hydration, correction of the acidosis and hyperkalemia, use of allopurinol and recombinant urate oxidase (rasburicase) for preventing urate nephropathy and haemodialysis. The authors report a case of a patient with acute myeloid leukemia, who developed severe tumor lysis syndrome after chemotherapy.
Méhes
Leonóra
L
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Belgyógyászati Intézet, II. Belgyógyászati Klinika, Hematológiai Tanszék, Debrecen. mehes_leonora@yahoo.com
Udvardy
Miklós
M
Szász
Róbert
R
Rejto
László
L
D000138:Acidosis / Q000209:etiology / Q000628:therapy; D058186:Acute Kidney Injury / Q000150:complications / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D000493:Allopurinol / Q000008:administration & dosage; D005440:Fluid Therapy; D006801:Humans; D006947:Hyperkalemia / Q000209:etiology / Q000628:therapy; D007684:Kidney Tubules / Q000378:metabolism*; D011994:Recombinant Proteins / Q000008:administration & dosage; D006435:Renal Dialysis; D015275:Tumor Lysis Syndrome / Q000150:complications / Q000378:metabolism; D014503:Urate Oxidase / Q000008:administration & dosage; D014527:Uric Acid / Q000378:metabolism*
D011994:Recombinant Proteins; C469709:rasburicase; D014527:Uric Acid; D000493:Allopurinol; D014503:Urate Oxidase